Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026)

Intellia Therapeutics (NTLA) reported Non Operating Investment Income of -$904000.0 for Q1 2026, down 300.0% year-over-year from $452000.0 in Q1 2025, and down 134.81% on a QoQ basis from -$385000.0 in Q4 2025.

Intellia Therapeutics (NTLA) has 8 years of Non Operating Investment Income data on file, last reported at -$904000.0 in Q1 2026.

  • Quarterly Non Operating Investment Income fell 300.0% year-over-year to -$904000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 94.79% YoY) and the FY2024 annual result came in at -$32.6 million, down 995.87% from the prior year.
  • Non Operating Investment Income declined to -$904000.0 in Q1 2026 per NTLA's latest filing, from -$385000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $3.6 million in Q4 2023 and bottomed at -$20.4 million in Q2 2024.
  • The 5-year median for Non Operating Investment Income is -$904000.0 (2026), against an average of -$2.2 million.
  • Peak annual rise in Non Operating Investment Income reached 715.53% in 2022, while the deepest fall reached 93100.0% in 2022.
  • Tracing NTLA's Non Operating Investment Income over 5 years: stood at $3.4 million in 2022, then climbed by 5.91% to $3.6 million in 2023, then slumped by 184.79% to -$3.1 million in 2024, then jumped by 87.51% to -$385000.0 in 2025, then plunged by 134.81% to -$904000.0 in 2026.
  • Per Business Quant, the three latest NTLA Non Operating Investment Income figures stand at -$904000.0 (Q1 2026), -$385000.0 (Q4 2025), and $337000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 235,807.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 230,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Intellia Therapeutics 1.63 Bn 1.63 Bn - -904,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -904,000.00
Mar 31, 2026 -904,000.00
Dec 31, 2025 -385,000.00
Dec 31, 2025 -385,000.00
Sep 30, 2025 337,000.00
Sep 30, 2025 337,000.00
Jun 30, 2025 -404,000.00
Jun 30, 2025 -404,000.00
Mar 31, 2025 452,000.00
Mar 31, 2025 452,000.00
Dec 31, 2024 -3.08 Mn
Dec 31, 2024 -3.08 Mn
Sep 30, 2024 -3.06 Mn
Sep 30, 2024 -3.06 Mn
Jun 30, 2024 -20.35 Mn
Jun 30, 2024 -20.35 Mn
Mar 31, 2024 -6.07 Mn
Mar 31, 2024 -6.07 Mn
Dec 31, 2023 3.64 Mn
Dec 31, 2023 3.64 Mn
Jun 30, 2023 -1.48 Mn
Jun 30, 2023 -1.48 Mn
Dec 31, 2022 3.43 Mn
Dec 31, 2022 3.43 Mn
Sep 30, 2022 991,000.00
Sep 30, 2022 991,000.00
Jun 30, 2022 -932,000.00
Jun 30, 2022 -932,000.00
Mar 31, 2022 -5.13 Mn
Mar 31, 2022 -5.13 Mn
Dec 31, 2021 -1.95 Mn
Dec 31, 2021 -1.95 Mn
Sep 30, 2021 -161,000.00
Sep 30, 2021 -161,000.00
Jun 30, 2021 -1,000.00
Jun 30, 2021 -1,000.00
Mar 31, 2021 -13,000.00
Mar 31, 2021 -13,000.00
Dec 31, 2020 -30,000.00
Dec 31, 2020 -30,000.00
Sep 30, 2020 -124,000.00
Sep 30, 2020 -124,000.00
Jun 30, 2020 -218,000.00
Jun 30, 2020 -218,000.00
Mar 31, 2020 112,000.00
Mar 31, 2020 112,000.00
Dec 31, 2019 -75,000.00
Dec 31, 2019 -75,000.00
Sep 30, 2019 81,000.00
Sep 30, 2019 81,000.00
Jun 30, 2019 196,000.00
Jun 30, 2019 196,000.00
Mar 31, 2019 87,000.00
Mar 31, 2019 87,000.00